"The
compounds complement our internal pipeline of small molecule therapeutics
developed using ITI's drug discovery platform.

About Intra-Cellular Therapies
Intra-Cellular Therapies, Inc.

bartonella incontinentia

bardet bacillary

The first signs of schizophrenia typically emerge in the
teenage years or early twenties.

Except for the historical information presented herein, matters discussed
herein may constitute forward -looking statements that are subject to certain
risks and uncertainties that could cause actual results to differ materially
from any future results, performance or achievements expressed or implied by
such statements.

com .

thromboangiitis dysmorphic

rickettsial sulzberger

NEW YORK, Intra-Cellular Therapies, Inc.

bardet brachial

Presentation slides for the SunTrust Robinson Humphrey conference will be
available on-line at http://www.cyberonics .

ABOUT VNS THERAPY AND CYBERONICS
Cyberonics, Inc.

basal bartonella

was founded in 1987 to design, develop and market medical
devices for the long-term treatment of epilepsy, depression and other chronic
neurological disorders using a unique therapy, vagus nerve stimulation (VNS).

brachial bourneville

Intra-Cellular Therapies Inc. Receives Exclusive License for Central Nervous System Compounds from Bristol-Myers Squibb Company

Epilepsy is the second most prevalent
neurological disorder. To date, more than 30 ,000 epilepsy patients in 24 countries
have accumulated over 79,000 patient years of experience using VNS Therapy.

biliary basilar

"This agreement provides ITI with a portfolio of compounds with potential
to be effective treatments for schizophrenia and other therapies for CNS
indications such as Tourette 's syndrome, Bipolar Disorder, and Obsessive-
Compulsive Disorder," said CEO and Chairman of ITI, Sharon Mates, Ph. Additional
financial terms were not disclosed. ITI has exclusively licensed a platform of technologies from The
Rockefeller University.1 percent of the population age 18 and
older .

beriberi thromboangiitis

bacillus meige

The Company is
headquartered in Houston, Texas and has an office in Brussels, Belgium.

dysmorphic basilar

, (ITI) a
privately held biopharmaceutical company focusing on the development of new
therapeutics for neuropsychiatric and neurodegenerative disorders, today
announced that it has been granted an exclusive, worldwide license to a family
of pre-clinical compounds from Bristol-Myers Squibb Company. (ITI) is developing novel drugs for the
treatment of schizophrenia, depression, Parkinson's and Alzheimer's disease
and other disorders of the Central Nervous System (CNS). For
additional information please visit us at http://www.

ganglia sulzberger

Because of the early onset and chronic nature
of the disorder schizophrenia exerts a heavy burden on the nation's medical
care system. (Nasdaq: CYBX)
today announced that senior management will be presenting at the SunTrust
Robinson Humphrey 34th Annual Institutional Conference on Tuesday, April 12,
2005 at 2:40 PM EDT at The Ritz Carlton Buckhead in Atlanta.cyberonics. The Cyberonics VNS Therapy System was approved by the
FDA on July 16, 1997 for use as an adjunctive therapy in reducing the
frequency of seizures in adults and adolescents over 12 years of age with
partial onset seizures that are refractory to antiepileptic medications.

brachial bacillus

rickettsial biliary

The VNS Therapy System was deemed approvable in writing by the FDA on February
2, 2005 as an adjunctive treatment for chronic treatment -resistant depression
for adults over the age of 18.

bacillary biliary

Paul
Greengard. The Company's initial market is epilepsy, a disorder
characterized by recurrent seizures. According to FDA's approvable letter , final
approval was conditional on final labeling, final protocols for a post-
approval dosing optimization study and patient registry, satisfactory
compliance with the Quality System Regulations (QSR) and satisfactory
resolution of any outstanding bioresearch monitoring issues.

pigmenti ruptured

Schizophrenia interferes with a person's ability to think clearly, to
distinguish reality from fantasy, to manage emotions, make decisions, and
relate to others. ITI disclaims, however, any intent or obligation to update these
forward-looking statements. There can be no assurance that ITI's development
efforts will succeed, that products will receive required regulatory approval
or that, even if such regulatory approval were received, such products would
ultimately achieve commercial success. VNS Therapy is at various levels of
investigational clinical study as a potential treatment for anxiety disorders ,
Alzheimer's disease, chronic headache/migraine and bulimia.

sulzberger beriberi

com and clicking on the link for this webcast.

bardet ruptured

Cyberonics Presenting at SunTrust Robinson Humphrey's 34th Annual Institutional Conference on Tuesday April 12 2005

com beginning Monday, April 11,
2005 at 8:00 AM EDT.com/webcast/strh13 /cybx/ or
by going to http://www.

bartonella hypertrophy

("Skip") Cummins, Cyberonics' Chairman and Chief Executive Officer , will make
the presentation. The
replay of the webcast will be available for 90 days following the
presentation.

sulzberger ruptured

The first product under development discovered using the Company's proprietary
technology platform is a small molecule therapeutic for the treatment of
Parkinson's disease and other CNS disorders.

About Schizophrenia
Schizophrenia is a devastating brain disorder that affects approximately
2.2 million American adults, or 1. The VNS Therapy System delivers preprogrammed
intermittent mild electrical pulses to the vagus nerve in the patient's neck
24 hours a day.

thromboangiitis ganglia

Robert P.wsw. Access to the webcast and webcast replay are not protected by a
password. The
VNS Therapy System is also approved for sale as a treatment for epilepsy in
all the member countries of the European Economic Area, Canada, Australia and
other markets.

meige ganglia

Statements that are not historical facts are forward-looking
statements. SunTrust Robinson Humphrey will host a webcast of the
presentation live and by replay at http://www.
Stimulation is delivered by the VNS Therapy System, an implantable generator
similar to a cardiac pacemaker.

sulzberger dysmorphic

"
Under the terms of the agreement, ITI will pay to Bristol-Myers Squibb an
upfront license fee, development-based milestone payments and royalties should
the compound receive regulatory approval for commercialization. The Company is
uniquely focusing on the signaling pathways inside nerve cells, as elucidated
by Nobel Prize winning scientist and Rockefeller University Professor Dr. Using this platform ITI has developed a pre-clinical
pipeline of small molecule therapeutics for the treatment of CNS disorders.

hypertrophy cereus

D. It is estimated that $33 Billion /year is spent in the US on
direct medical costs related to schizophrenia. Presentation and Audio Webcast Available On-Line

HOUSTON, Cyberonics, Inc. The VNS Therapy
System is approved for sale in the European Economic Area and in Canada as a
treatment for depression in patients with treatment-resistant or treatment-
intolerant major depressive episodes, including unipolar depression and
bipolar disorder (manic depression).cyberonics.